Induction of novel cell death focusing on the regulation of selenoprotein gene expression in refractory cancer

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K07063
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 49030:Experimental pathology-related
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Yamamoto Kouhei 東京医科歯科大学, 大学院医歯学総合研究科, 助教 (50451927)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: がん / 酸化ストレス / セレノプロテイン / SECIS配列 / SECISBP2 / 治療戦略

Outline of Final Research Achievements

proliferation was significantly reduced, and responsiveness to cell death stimuli was increased. Clinicopathological studies suggest that SECISBP2 is an independent prognostic predictor of DLBCL. In vitro, the protein levels of GPX4 and TXNRD1 were decreased in the SECISBP2-KO strain, and cell proliferation was significantly suppressed in the KO strain. Under doxorubicin administration, the SECISBP-KO strain was shown to have a significantly higher mortality. It was suggested that the SECIS sequence and SECISBP2 may be useful as new antitumor targets.

Free Research Field

病理学、血液腫瘍学

Academic Significance and Societal Importance of the Research Achievements

難治性の悪性リンパ腫に対して、これまでにない新しい治療戦略を提唱できた点で学術的にも社会的にも大変意義のある研究が遂行されたと考えている。